Canadian scientists present new research findings at Pacifichem 2000

December 16, 2000

Papers are embargoed until date and time of presentation.

Click here for Abstract 1, here for Abstract 2, and here for Abstract 3.

HONOLULU - The latest research from Canadian scientists will be presented at the 2000 International Chemical Congress of Pacific Basin Societies, December 14-19, 2000.

The weeklong scientific meeting, held once every five years, is hosted by the American Chemical Society, in conjunction with its counterparts in Australia, Canada, Japan and New Zealand.

Canadian chemists will present new medical findings on topics including (papers are embargoed for release until date and time of presentation):

Chronic pain - As part of an ongoing search for better drugs for pain, researchers in Canada are developing a class of drugs (nonpeptidic opioid receptor agonists) that could have fewer side effects and a lower potential for abuse. At least one appears promising as an oral drug for the treatment of chronic pain. (MEDI 12, 8:45 a.m., Thursday, Dec. 14)

Hepatitis C - Hepatitis C virus (HCV), a major disease worldwide, has no known cure. But researchers are developing potent, highly specific inhibitors of HCV protease, an enzyme involved in the maturation of the virus, that may lead to effective treatments of the disease. (MEDI 557, 1:35 p.m., Friday, Dec. 15)

Non-insulin dependent diabetes - Researchers have identified a promising new target for the treatment of non-insulin dependent diabetes and the prevention of obesity. The enzyme target, protein tyrosine phosphatase (PTB-1B), appears to be a key regulator of metabolism. In studies of mice put on high fat diets to induce diabetes and obesity, blocking this enzyme resulted in lean mice that were insulin sensitive. (MEDI 236, 9:20 a.m., Sunday, Dec. 17)

More than 8,000 research papers will be presented during this year's International Chemical Congress, which is sponsored jointly by the ACS, the Chemical Society of Japan, the Canadian Society of Chemistry, the Royal Australian Chemical Institute and the New Zealand Institute of Chemistry.

American Chemical Society

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to